Caloric Restriction Mimetic Combination Therapy (Metformin + Resveratrol + Rapamycin) Achieves Synergistic Neuronal Longevity via Coordinated AMPK-SIRT1-mTOR Axis Activation
🧪 Overview
Caloric restriction (CR) extends lifespan and improves neuronal function across species through a network of interconnected metabolic sensors: AMPK (activated by increased AMP/ATP ratio), SIRT1 (activated by increased NAD+/NADH ratio), and mTORC1 (inhibited by reduced amino acid signaling and increased AMPK activity). This hypothesis proposes that a rationally designed combination of FDA-approved caloric restriction mimetics—metformin (AMPK activator, via mitochondrial complex I inhibition), resveratrol (SIRT1 activator, via NAD+ boost and direct SIRT1 binding), and low-dose rapamycin (mTORC1 inhibitor, via FKBP1A binding)—will achieve synergistic neuronal longevity effects that exceed the therapeutic potential of any single agent in AD and PD models. The mechanistic basis for synergy is the feedforward loop where metformin-induced AMPK activation increases NAD+ levels (via improved mitochondrial function and reduced PARP1 consumption), which supports SIRT1 activation, which in turn deacetylates and activates PGC1α and FOXO3a, enhancing mitochondrial biogenesis and stress resistance.
...🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["Metformin Complex I Inhibition<br/>AMP/ATP Ratio Rises"]
B["AMPK Activation<br/>Energy Sensor Engaged"]
C["NAD+ Levels Rise<br/>Improved Mitochondrial Function"]
D["Resveratrol SIRT1 Direct Binding<br/>Deacetylase Activity Enhanced"]
E["SIRT1 Deacetylates PGC1alpha FOXO3a<br/>Mitochondrial Biogenesis Stress Resistance"]
F["Rapamycin FKBP12 Complex<br/>mTORC1 Inhibition"]
G["Autophagy Derepressed<br/>Proteostasis Restored"]
H["Synergistic Neuronal Longevity<br/>28 percent Lifespan Extension vs 8-12 percent Each"]
A --> B
B --> C
C --> D
D --> E
E --> H
F --> G
G --> H
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — AMPK
No curated PDB or AlphaFold mapping for AMPK yet. Search RCSB →
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for AMPK,PRKAA1,PRKAA2,SIRT1,MTOR,RPTOR,PPARGC1A,FOXO3,FOLH1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF individuals aged 50-55 with elevated CSF neurofilament light chain (NfL >100 pg/mL) or positive amyloid PET (SUVR >1.2) are treated with oral metformin (1000mg/day) + resveratrol (500mg/day) + low- | White matter atrophy rate <0.5%/year (vs. ≥1.0%/year in control), cognitive decline prevented (MMSE maintenance, <1 point/year loss), and progression to MCI red | — no observation — | pending | 0.55 |
| IF 10-12 month old SAMP8 mice are treated daily for 6 months with oral metformin (200mg/kg) + resveratrol (200mg/kg) + rapamycin (5mg/kg) in triple combination versus each agent individually at equiva | Morris water maze latency reduced by ≥40% in triple therapy vs. ≤25% in best monotherapy, with significantly longer rotarod latency (≥35% improvement) indicatin | — no observation — | pending | 0.65 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |